YO39523/GOG-3015: A PHASE III, MULTICENTER, RANDOMIZED, STUDY OF ATEZOLIZUMAB VERSUS PLACEBO ADMINISTERED IN COMBINATION WITH PACLITAXEL, CARBOPLATIN, AND BEVACIZUMAB TO PATIENTS WITH NEWLY-DIAGNOSED STAGE III OR STAGE IV OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER
Study of New Drug Combination in Patients with Newly-Diagnosed Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Sponsor: F. Hoffmann- La Roche Ltd.
Enrolling: Female Patients Only
IRB Number: AAAR3798
U.S. Govt. ID: NCT03038100
Contact: Reena Vattakalam: 212-342-6895 / rmv2110@cumc.columbia.edu
Additional Study Information: Atezolizumab is an antibody that affects your immune system by blocking the PD L1 pathway. An antibody is a large, Y-shaped protein used by your body's immune system to identify and kill foreign objects, such as bacteria, viruses, and tumor cells. The PD L1 pathway is involved in the decrease of your body's natural immune response to fight cancer. By blocking the PD-L1 pathway, atezolizumab may help your immune system to stop or reverse the growth of tumors. You will also receive treatment with paclitaxel, carboplatin, and bevacizumab. These chemotherapy based treatments are standard for patients with your specific type of cancer. In addition to these standard treatments, you will receive either atezolizumab or a placebo.
This study is closed
Investigator
Jason Wright, MD
Do You Qualify?
Have you been diagnosed with ovarian cancer, peritoneal primary carcinoma, or fallopian tube cancer? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder




For more information, please contact:
Reena Vattakalam
rmv2110@cumc.columbia.edu
212-342-6895